黄芪建中汤防治脾胃虚寒型胃癌的临床研究

王其进; 张达坤; 蔡媛媛

doi:10.3969/j.issn.1671-038X.2016.02.07

黄芪建中汤防治脾胃虚寒型胃癌的临床研究

- 海南省中医院消化科, 海南海口 570203

详细信息

作者简介:
王其进,硕士,主治医师,主要从事消化系疾病中医药防治基础与临床研究

中图分类号: R735.2

收稿日期: 2015-07-14

Clinical study of Huangqijianzhong Decoction on treating the deficiency of spleen-Yang of gastric cancer

- Department of Gastroenterology, Chinese Medicine Hospital of Hainan Province, Haikou 570203, China

Received Date: 14 July 2015

摘要

摘要: [目的]观察胃癌患者治疗前后Kaiso、Flotillin-1 mRNA表达变化，探讨黄芪建中汤防治胃癌的机制研究。[方法]50例符合诊断标准、纳入标准、排除标准的胃癌患者按就诊顺序1：1分为对照组与治疗组，对照组给予化疗药物治疗，治疗组给予黄芪建中汤联合化疗药物治疗，2组均为3个疗程。应用Karnofsky评分记录2组患者治疗前后生活质量积分变化，应用实时荧光定量PCR技术检测2组治疗前、后Kaiso、Flotillin-1的表达变化。[结果]全部病例完成临床观察，治疗组完全缓解0例、部分缓解9例、稳定10例、进展6例，总有效率为76%；对照组完全缓解0例、部分缓解8例、稳定8例、进展9例，总有效率为64%；2组比较，差异有统计学意义（P<0.05）。治疗前Kaiso、Flotillin-1表达呈上升趋势；治疗后，治疗组Kaiso、Flotillin-1表达呈下降趋势，较治疗前差异有统计学意义（P<0.05）。对照组Kaiso、Flotillin-1表达较治疗前无明显变化。[结论]黄芪建中汤可能通过调控Kaiso、Flotillin-1表达水平，有效缓解胃癌患者临床症状，发挥协同治疗作用。
- Kaiso /
- Flotillin-1 /
- 胃癌 /
- 脾胃虚寒
Abstract: [Objective] To explore the effect of Huangqijianzhong Decoction on the expression of Kaiso and Flotillin-1 mRNA in gastric cancer patients and to investigate the underlying mechanisms.[Methods] Fifty patients who met the diagnostic criteria, inclusion criteria and exclusion criteria of gastric cancer were divided into control group and treatment group according to the order of treatment.The control group was given chemotherapy drug, and the treatment group was given Huangqijianzhong decoction combined with chemotherapy drug.The treatment lasted 3 courses.The life quality score was recorded according to Karnofsky score before and after treatment.The expression of Flotillin-1 and Kaiso were detected by real-time PCR.[Results] All the patients completed the clinical observation.The total efficiency was 76% in treatment group and 64% in control group.There was statistical significant difference between the two groups(P<0.05).Before the treatment, the expression of Flotillin-1 and Kaiso were increased.Then the expression of Flotillin-1 and Kaiso were decreased after the treatment.The expression of Kaiso and Flotillin-1 in the control group had no significant change.[Conclusion] Huangqijianzhong Decoction can effectively improve clinical symptoms of gastric cancer by regulating the expression of Kaiso and Flotillin-1.
- Kaiso /
- Flotillin-1 /
- gastric cancer /
- deficiency of spleen-Yang

HTML全文

参考文献(27)

[1]	赵红, 相宏杰, 曹志群.昆参颗粒治疗进展期胃癌的临床研究[J].时珍国医国药, 2011, 22(5):1196-1197.
[2]	DONALDSON N S, PIERRE C C, ANSTEY M I, et al.Kaiso represses the cel cycle gene cyclin D1via sequence-speccific and methyl-CpG-dependent mechanisms[J].PLoS One, 2012, 7:e50398.
[3]	GIRARDOT N, ALINQUANT B, DUYCKAERTS C.Lipid rafts, flotillin-1and Alzheimer disease[J].Jsoc Biol, 2003, 197:223-229.
[4]	LIU N N, WANG Y, LIU X, et al.Helicobacter pylori-induced VEGF expressions in human gastric cancer MKN 45cells mediated by COX-2[J].Chin Oncol, 2010, 20:1-5.
[5]	粱进, 毕清, 杨润祥.多西他赛联合奥沙利铂治疗进展期胃癌的临床观察[J].实用癌症杂志, 2007, 22(5):501-502.
[6]	张昉, 陈雅敏, 荆超, 等.改良DCF方案与FOLFOX 4方案治疗晚期胃癌的临床疗效[J].临床肿瘤学杂志, 2014, 19(3):231-234.
[7]	中华中医药学会.中医内科常见疾病诊疗指南·西医疾病部分[M].北京:中国中医药出版社.2008:123-136.
[8]	PARKIN D M, BRAY F, FERLAY J, et al.Global cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55:74-108.
[9]	陆彬彬, 王朝霞, 王莉, 等.参蔑扶正注射液对胃癌术后DFC方案辅助治疗毒副反应影响的临床观察[J].现代肿瘤医学, 2013, 21(3):599-600.
[10]	张曦, 章永红.胃癌的中医药治疗研究[J].长春中医药大学学报, 2012, 28(2):274-275.
[11]	王洪真.DCF方案联合扶正和胃汤治疗进展期胃癌34例临床观察[J].中国中西医结合杂志, 2007, 27(10):927-928.
[12]	朱超林, 薛维伟, 潘宇.胃癌中医病名定义规范化研究探讨[J].时珍国医国药, 2012, 23(6):1489-1490.
[13]	郑小伟, 陆红虎, 于纪红.黄芪建中汤配伍特点及临床应用浅析[J].浙江中医杂志, 2010, 45(9):678-678.
[14]	徐升, 马佳铭, 杨帆, 等.黄芪建中汤对胃黏膜损伤模型大鼠MMP-2及TIMP-1表达的影响[J].中华中医药杂志, 2011, 26(9):2116-2118.
[15]	宋红, 郑小伟, 王颖, 等.加味黄芪建中汤对脾气虚证大鼠胃泌素基因表达的影响[J].中华中医药杂志, 2008, 23(2):121-124.
[16]	刘旺根, 蒋时红, 冯黎, 等.黄芪建中汤对脾虚型慢性萎缩性胃炎大鼠免疫功能的影响[J].浙江中医杂志, 2007, 42(7):387-389.
[17]	包素珍, 郑小伟, 宋红.黄芪建中汤对脾气虚证肺癌转移小鼠T1 MP1基因转录的影响[J].中华中医药学刊, 2012, 30(4):686-688.
[18]	朱超林, 薛维伟, 潘宇.胃癌中医病名定义规范化研究探讨[J].时珍国医国药, 2012, 23(6):1489-1490.
[19]	IIOKA H, DOERNER S K, TAMAI K.Kaiso is a bimodal modulator for Wnt/beta-catenin signaling[J].FEBS Lett, 2009, 583:627-632.
[20]	KOURTIDIS A, NGOK S P, ANASTASIADIS P Z.pl20catenin:an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression[J].Prog Mol Biol Transl Sci, 2013, 11:409-432.
[21]	LIU Y, DONG Q Z, WANG S, et al.Kaiso interacts with p120-catenin to regulate beta-catenin expression at the transcriptional level[J].PLoS One, 2014, 9:e87537.
[22]	BREMBECK F H, ROSARIO M, BIRCHMEIER W.Balancing cell adhesion and Wnt signaling, the key role of beta-catenin[J].Curr Opin Genet Dev, 2006, 16:51-59.
[23]	SHERBET G V, LAKSHMI M S.S100 A4(MTS1) calcium binding protein in cancer growth, invasion and metastasis[J].Anticancer Res, 1998, 18:2415-2421.
[24]	CAO K, XIE D, CAO P, et al.SiRNA-mediated flotillin-2(Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells[J].Oncol Res, 2014, 21:271-279.
[25]	YAN Y, YANG F Q, ZHANG H M, et al.Up-regulation of flotillin-2is associated with renal cell carcinoma progression[J].Tumour Biol, 2014, 35:10479-10486.
[26]	ZHU Z, WANG J, SUN Z, et al.Flotillin2expression correlates with HER2levels and poor prognosis in gastric cancer[J].PLoS One, 2013, 8:e62365.
[27]	GAO W, XU J, WANG F, et al.Plasma membrane proteomic analysis of human gastric cancer tissues:revealing flotillin-1as a marker for gastric cancer[J].BMC Cancer, 2015, 15:367-367.